Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
| Member | Definition | Class |
|---|
| 1-octanesulfonic acid | | octane-1-sulfonic acid |
| benoxinate | A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. | oxybuprocaine |
| benoxinate hydrochloride | The monohydrochloride salt of oxybuprocaine. | oxybuprocaine hydrochloride |
| benzydamine | A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. | benzydamine |
| bromoethane | A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses. | bromoethane |
| buclizine | An N-alkylpiperazine carrying (4-chlorophenyl)(phenyl)methyl and 4-tert-butylbenzyl groups. | buclizine |
| bupivacaine hydrochloride | A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic. | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride; bupivacaine hydrochloride (anhydrous) |
| butamben | An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders. | butamben |
| cassaine | A tricyclic diterpenoid isolated from several plant species of the genus Erythrophleum. | cassaine |
| chloroprocaine | Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding. | chloroprocaine |
| cocaine | A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca. | cocaine |
| cocaine hydrochloride | The hydrochloride salt of cocaine. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. | cocaine hydrochloride |
| cyclizine | An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group. | cyclizine |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| ethyl chloride | The simplest and least toxic member of the class of chloroethanes, that is ethane in which a single hydrogen is substituted by a chlorine. A colourless gas at room temperature and pressure (boiling point 12degreeC), it is used as a mild topical anaesthetic to numb the skin prior to ear piercing, skin biopsies, etc., and is also used in the treatment of sports injuries. It was formerly used in the production of tetraethyllead. | chloroethane |
| etidocaine | An amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery. | etidocaine |
| levobupivacaine | The (S)-(-)-enantiomer of bupivacaine. | levobupivacaine |
| levobupivacaine hydrochloride | The monohydrochloride salt of levobupivacaine. | levobupivacaine hydrochloride (anhydrous) |
| lidocaine | The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline. | lidocaine |
| lidocaine hydrochloride | The anhydrous form of the hydrochloride salt of lidocaine. | lidocaine hydrochloride |
| lidocaine hydrochloride | The monohydrate form of lidocaine hydrochloride. | lidocaine hydrochloride monohydrate |
| mepivacaine | A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic. | mepivacaine |
| mepivacaine hydrochloride | The hydrochloride salt of mepivacaine. It is used as a local anaesthetic. | mepivacaine hydrochloride |
| oxybutynin | A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder. | 4-(diethylamino)but-2-yn-1-ol; oxybutynin |
| phenazopyridine | A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | phenazopyridine |
| phenazopyridine hydrochloride | A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | phenazopyridine hydrochloride |
| pramoxine | A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group. | pramocaine |
| prilocaine | An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic. | prilocaine |
| prilocaine hydrochloride | The monohydrochloride salt of prilocaine. | prilocaine hydrochloride |
| procaine | A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol. | procaine |
| promethazine | A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. | promethazine |
| promethazine hydrochloride | The hydrochloride salt of promethazine. | promethazine hydrochloride |
| qx-314 | | QX-314 |
| ropivacaine | The anhydrous form of (S)-ropivacaine hydrochloride. | (S)-ropivacaine hydrochloride (anhydrous) |
| ropivacaine | A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond. | (S)-ropivacaine |
| tetracaine | A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia. | tetracaine |
| tocainide | A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic. | tocainide |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 32.4648 | 1 | 2 |
| 67.9K protein | Vaccinia virus | Potency | 28.1838 | 1 | 1 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 48.2367 | 4 | 8 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 24.6306 | 1 | 2 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3563 | 1 | 4 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 28.0834 | 10 | 54 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 22.0467 | 3 | 14 |
| arylsulfatase A | Homo sapiens (human) | Potency | 3.7144 | 1 | 3 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.6055 | 2 | 4 |
| Ataxin-2 | Homo sapiens (human) | Potency | 22.6820 | 2 | 8 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 16.9069 | 1 | 2 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 22.2330 | 2 | 12 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0048 | 2 | 4 |
| BRCA1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 30.0149 | 1 | 3 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 68.5896 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 68.5896 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 43.5291 | 2 | 15 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 8.6242 | 1 | 3 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 21.0906 | 1 | 4 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 25.7877 | 1 | 2 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 28.8193 | 1 | 3 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 543.1903 | 1 | 3 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 18.9868 | 1 | 4 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 74.2035 | 2 | 7 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 8.9716 | 1 | 2 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 22.7496 | 1 | 3 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.3023 | 1 | 3 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 13.9980 | 1 | 11 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 11.1348 | 1 | 8 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.2452 | 2 | 16 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 13.9312 | 2 | 10 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 17.6123 | 1 | 6 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 4.6148 | 2 | 3 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 14.6892 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 3.9811 | 1 | 2 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 69.9577 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 50.1187 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 24.4174 | 12 | 69 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 35.6213 | 2 | 11 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 31.5260 | 7 | 41 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.8833 | 2 | 16 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 29.0189 | 3 | 3 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 2 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 42.5715 | 2 | 6 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 54.2184 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 34.3273 | 1 | 2 |
| G | Vesicular stomatitis virus | Potency | 16.3023 | 1 | 3 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.2452 | 1 | 8 |
| geminin | Homo sapiens (human) | Potency | 15.7893 | 3 | 13 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 14.1858 | 2 | 17 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| GLS protein | Homo sapiens (human) | Potency | 20.1441 | 2 | 7 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.7692 | 4 | 17 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 18.5045 | 1 | 6 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 12.9953 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 49.2479 | 1 | 1 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 16.0599 | 3 | 4 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 20.6038 | 2 | 15 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 11.6071 | 1 | 4 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 12.2815 | 2 | 6 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 70.2233 | 1 | 5 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.3023 | 1 | 3 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 31.8326 | 1 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 48.9722 | 1 | 1 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 7.7401 | 2 | 6 |
| IDH1 | Homo sapiens (human) | Potency | 2.0618 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 12.9953 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.3023 | 1 | 6 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 0.8013 | 2 | 4 |
| Interferon beta | Homo sapiens (human) | Potency | 12.2271 | 2 | 4 |
| interleukin 8 | Homo sapiens (human) | Potency | 118.8320 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 11.9708 | 1 | 12 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 0.1585 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 17.5809 | 4 | 10 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 30.1076 | 2 | 4 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 33.2451 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 11.0333 | 2 | 9 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 16.4707 | 2 | 10 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 14.7707 | 2 | 10 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 5.6234 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 30.1076 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 30.1076 | 1 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 26.1150 | 4 | 19 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.6462 | 1 | 2 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 11.0388 | 1 | 2 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 45.3996 | 1 | 3 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 9.0933 | 2 | 6 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 32.4696 | 3 | 25 |
| P53 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 15.7636 | 2 | 5 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 84.9214 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.2284 | 4 | 10 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 42.7664 | 5 | 8 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 59.6848 | 1 | 3 |
| polyprotein | Zika virus | Potency | 34.3273 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 17.3851 | 1 | 3 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 16.6007 | 1 | 7 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 25.5822 | 3 | 15 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 23.4451 | 1 | 2 |
| progesterone receptor | Homo sapiens (human) | Potency | 41.2611 | 2 | 8 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 16.9064 | 2 | 19 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 9.1010 | 1 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 23.0452 | 3 | 26 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 37.6088 | 4 | 9 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 14.6892 | 2 | 2 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 49.4759 | 1 | 1 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 49.4759 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 12.9953 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 32.5597 | 1 | 3 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 16.4450 | 1 | 4 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 12.8162 | 1 | 4 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.6519 | 2 | 18 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 15.1010 | 3 | 9 |
| Thrombopoietin | Homo sapiens (human) | Potency | 0.0631 | 2 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 36.4231 | 3 | 28 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 2.2740 | 1 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 28.8670 | 5 | 14 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 17.3768 | 1 | 1 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 30.6694 | 1 | 2 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 3.9811 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.2635 | 1 | 6 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 18.4301 | 2 | 13 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 42.9977 | 4 | 6 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 96.3750 | 1 | 3 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 18.5045 | 1 | 6 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 2.5960 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.8925 | 2 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 2.5960 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.8925 | 2 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 1.0050 | 2 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 0.0855 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.3572 | 1 | 4 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.5878 | 1 | 4 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.0855 | 2 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.3740 | 1 | 4 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 1.3203 | 1 | 4 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.0855 | 2 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.6916 | 1 | 4 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 1.3202 | 1 | 4 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.6916 | 1 | 4 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 2.4290 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 1.1280 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 35.1000 | 1 | 2 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.3010 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 3.4584 | 1 | 3 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 3.4299 | 1 | 3 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.6990 | 1 | 2 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.3435 | 1 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 1.1160 | 1 | 2 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 5.7544 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.4190 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0530 | 1 | 1 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 5.7544 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 2.4310 | 1 | 1 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 5.7544 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.3530 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 0.3170 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 0.3380 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Ki | 0.0059 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 31.8590 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 26.1013 | 1 | 1 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 302.3800 | 4 | 15 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Calmodulin-1 | Homo sapiens (human) | IC50 | 60.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | Ki | 1.1150 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | Ki | 1.1150 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | Ki | 1.1150 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| Chloroquine resistance transporter | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 85.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 0.6000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 2.2713 | 1 | 3 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 2 |
| D | Rattus norvegicus (Norway rat) | IC50 | 5.7544 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 2.7440 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 1.3720 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.4395 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.2600 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.3300 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 1.3266 | 1 | 3 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.4505 | 1 | 3 |
| Fatty acid-binding protein, heart | Homo sapiens (human) | IC50 | 0.3670 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.0543 | 2 | 4 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0099 | 2 | 4 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.1650 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.1460 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 42.6579 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | Ki | 0.5240 | 1 | 1 |
| Leukotriene B4 receptor 2 | Homo sapiens (human) | Ki | 0.5240 | 1 | 1 |
| Lysosomal Pro-X carboxypeptidase | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| MBT domain-containing protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | IC50 | 54.3000 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.9654 | 2 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 4 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.2596 | 1 | 4 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 0.0423 | 3 | 6 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 40.9343 | 3 | 3 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.5675 | 1 | 4 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.1204 | 4 | 7 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 0.0105 | 2 | 2 |
| Muscarinic acetylcholine receptor M2 | Sus scrofa (pig) | Ki | 0.2344 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 0.3544 | 1 | 4 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.0435 | 4 | 7 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.0031 | 2 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.3084 | 1 | 4 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.0352 | 2 | 5 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.2007 | 1 | 4 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.1182 | 2 | 5 |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | IC50 | 145.0000 | 1 | 1 |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | Ki | 70.0000 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 31.8590 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 26.1013 | 1 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 17.7000 | 1 | 1 |
| Potassium channel subfamily K member 18 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | IC50 | 193.5000 | 2 | 2 |
| Potassium channel subfamily K member 3 | Homo sapiens (human) | IC50 | 338.2000 | 1 | 5 |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 | 2,188.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | IC50 | 1,210.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 135.9789 | 15 | 26 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 26.1013 | 1 | 1 |
| Procathepsin L | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| Protein orai-2 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Protein orai-3 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Human coronavirus 229E | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 18.4300 | 2 | 3 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.7009 | 2 | 6 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 1.9428 | 2 | 5 |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | IC50 | 54.3000 | 1 | 1 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 56.0000 | 1 | 2 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 0.7950 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 56.0000 | 1 | 2 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 5.6200 | 2 | 2 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 56.0000 | 1 | 2 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 25.1717 | 6 | 6 |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | IC50 | 0.0560 | 1 | 1 |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | IC50 | 0.5200 | 1 | 1 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 | 5.4023 | 7 | 7 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | Ki | 6.2500 | 2 | 2 |
| Sodium-dependent dopamine transporter | Mus musculus (house mouse) | IC50 | 0.2000 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 1.3496 | 47 | 67 |
| Sodium-dependent dopamine transporter | Mus musculus (house mouse) | Ki | 0.8500 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 25.2495 | 26 | 41 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 0.3726 | 38 | 39 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.4124 | 32 | 36 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 1.5115 | 24 | 26 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 1.7835 | 33 | 37 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.9646 | 25 | 25 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 0.8885 | 15 | 18 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.4112 | 34 | 37 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 0.5433 | 19 | 28 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 24.0000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 35.1000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 32.0000 | 1 | 1 |
| Spike glycoprotein | Betacoronavirus England 1 | IC50 | 13.6450 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Transmembrane protease serine 2 | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| Transporter | Rattus norvegicus (Norway rat) | IC50 | 3.2277 | 13 | 15 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 2.3415 | 16 | 19 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 271.0000 | 1 | 1 |
| Trypanothione reductase | Trypanosoma cruzi | Ki | 216.0000 | 1 | 1 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | Ki | 0.4900 | 1 | 1 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 18.0000 | 1 | 1 |